<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404441</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2101</org_study_id>
    <secondary_id>2014-003929-17</secondary_id>
    <nct_id>NCT02404441</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of PDR001 in Patients With Advanced Malignancies</brief_title>
  <official_title>Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this &quot;first-in-human&quot; study of PDR001 was to characterize the safety,&#xD;
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001&#xD;
      administered i.v. as a single agent to adult patients with solid tumors.&#xD;
&#xD;
      By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, PDR001 inhibits&#xD;
      the PD-1 immune checkpoint, resulting in activation of an antitumor immune response by&#xD;
      activating effector T-cells and inhibiting regulatory T-cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a phase I/II, multi-center, open-label study starting with a phase&#xD;
      I dose escalation part followed by a phase II part.&#xD;
&#xD;
      Although the study had 2 'arms', the phase I part of the study had 5 dosing cohorts and the&#xD;
      phase ll part had 5 treatment groups for a total of 10 reporting groups.&#xD;
&#xD;
      PDR001 was administered every 2 weeks until patient experienced unacceptable toxicity,&#xD;
      progressive disease per immune related Response Criteria (irRC) and/or treatment was&#xD;
      discontinued at the discretion of the investigator or the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2015</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Although the study had 2 'arms', the phase I part of the study had 5 dosing cohorts and the phase ll part had 5 treatment groups for a total of 10 reporting groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days)</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 3)</time_frame>
    <description>Estimated the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) for PDR001.&#xD;
AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase l: Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>8 months</time_frame>
    <description>DLT is defined as an adverse event (AE) or abnormal laboratory value of common terminology criteria for adverse events (CTCAE) grade â‰¥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first cycle of treatment with PDR001 during the dose escalation part of the study for which relationship to study treatment cannot be ruled out, with some exceptions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase ll: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</measure>
    <time_frame>61 months</time_frame>
    <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required.&#xD;
PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Serum Pharmacokinetic (PK) Parameter AUCs (AUC0-336h (Cycle 1 Only), AUCinf, AUClast AUCtau)</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
    <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Serum Pharmacokinetic (PK) Parameter Cmax</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
    <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Serum Pharmacokinetic (PK) Parameter Tmax</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
    <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase ll: Serum Pharmacokinetic (PK) Parameter AUCs (AUC336h, AUCinf, AUClast, AUCtau)</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
    <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase ll: Serum Pharmacokinetic (PK) Parameter Cmax</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
    <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase ll: Serum Pharmacokinetic (PK) Parameter Tmax</measure>
    <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
    <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Presence and/or Concentration of Anti-PDR001</measure>
    <time_frame>42 months</time_frame>
    <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Presence and/or Concentration of Anti-PDR001</measure>
    <time_frame>42 months</time_frame>
    <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.&#xD;
For Treatment -induced ADA-positive, Percentage was based on subjects ADA-negative at baseline.&#xD;
For Treatment-boosted ADA-positive, Percentage was based on subjects ADA-positive at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l: Overall Response Rate (ORR) as Per Investigator Based on RECIST v1.1</measure>
    <time_frame>27 months</time_frame>
    <description>ORR is the percentage of participants with a best overall response of complete response CR or partial response PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</measure>
    <time_frame>27 months</time_frame>
    <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l: Progression Free Survival (PFS) as Per RECIST v1.1</measure>
    <time_frame>27 months</time_frame>
    <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Duration of Response (DOR) as Per RECIST v1.1</measure>
    <time_frame>27 months</time_frame>
    <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented. CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required; PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required; PD =progression &lt;= 12 weeks after randomization/start of treatment (and not qualifying for CR, PR or SD). SD = at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR). RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l Only: Overall Response Rate (ORR) as Per Investigator Based on Immune Related Response Criteria (irRC)</measure>
    <time_frame>27 months</time_frame>
    <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l Only: Disease Control Rate (DCR) as Per Investigator Based on irRC</measure>
    <time_frame>27 months</time_frame>
    <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase l Only: Progression Free Survival (PFS) as Per irRC</measure>
    <time_frame>27 months</time_frame>
    <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Duration of Response (DOR) as Per irRC</measure>
    <time_frame>61 Days</time_frame>
    <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</measure>
    <time_frame>61 months</time_frame>
    <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression Free Survival as Per Investigator Based on RECIST v1.1</measure>
    <time_frame>61 months</time_frame>
    <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Duration of Response (DOR) as Per Investigator Based on RECIST v1.1</measure>
    <time_frame>61 months</time_frame>
    <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
PD = progression &lt;= start of treatment (and not qualifying for CR, PR or SD). SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Response Rate (ORR) as Per Investigator Based on irRC</measure>
    <time_frame>61 months</time_frame>
    <description>ORR is the percentage of participants with a best overall response CR or PR as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Disease Control Rate (DCR) as Per Investigator Based on irRC</measure>
    <time_frame>61 months</time_frame>
    <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression Free Survival (PFS) Per irRC</measure>
    <time_frame>61 months</time_frame>
    <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Duration of Response (DOR) Per irRC</measure>
    <time_frame>61 months</time_frame>
    <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Sell Lung Cancer (NSCLC)</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Anaplastic Thyroid Cancer</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>patients with solid tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase I Dose escalation cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selected tumor types</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>anti-PD1 antibody</description>
    <arm_group_label>Selected tumor types</arm_group_label>
    <arm_group_label>patients with solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must have been obtained prior to any screening procedures&#xD;
&#xD;
          -  Phase I part: Patients with advanced/metastatic solid tumors, with measurable or&#xD;
             non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who&#xD;
             have progressed despite standard therapy or are intolerant of standard therapy, or for&#xD;
             whom no standard therapy exists.&#xD;
&#xD;
          -  Phase II part: Patients with advanced/metastatic solid tumors, with at least one&#xD;
             measurable lesion as determined by RECIST version 1.1, who have progressed following&#xD;
             their last prior therapy, and fit into one of the following groups:&#xD;
&#xD;
               -  Group 1a and 1b: NSCLC:&#xD;
&#xD;
        Patients with NSCLC must have had disease recurrence or progression during or after no more&#xD;
        than one prior systemic chemotherapy regimen (platinum doublet-based) for advanced or&#xD;
        metastatic disease. Prior maintenance therapy is allowed (e.g. pemetrexed, erlotinib,&#xD;
        bevacizumab).&#xD;
&#xD;
        Only patients with EGFR mutation-negative tumor are eligible (defined as negative for exon&#xD;
        19 deletions and for the L858R mutation in EGFR at a minimum; however, if more extensive&#xD;
        EGFR mutation testing has been performed, the tumor must not harbor any known activating&#xD;
        EGFR mutations in Exons 18-21 in order to be considered EGFR mutation-negative). All&#xD;
        patients must be tested for EGFR mutational status and, for ALK translocation status if no&#xD;
        mutation is detected in EGFR. Patients with ALK translocation-positive NSCLC must have had&#xD;
        disease progression following treatment with a corresponding inhibitor and no more than one&#xD;
        systemic chemotherapy regimen (platinum doublet-based), in any sequence.&#xD;
&#xD;
          -  Group 2: Melanoma:&#xD;
&#xD;
        All patients must have been tested for BRAF mutations. Patients with V600 mutation positive&#xD;
        melanoma must have clinical or radiological evidence of disease progression during or after&#xD;
        treatment with a BRAF inhibitor alone or in combination with other agents.&#xD;
&#xD;
          -  Group 3: Triple negatice breast cancer.&#xD;
&#xD;
          -  Group 4: Anaplastic thyroid cancer&#xD;
&#xD;
          -  Patients are not required to have received or progressed on a prior therapy.&#xD;
&#xD;
          -  Patients must not be at short term risk for life threatening complications (such as&#xD;
             airway compromise or bleeding from locoregional or metastatic disease).&#xD;
&#xD;
          -  Chemoradiation and/or surgery should be considered prior to study entry for those&#xD;
             patients with locally advanced disease if those therapies are considered to be in the&#xD;
             best interest of the patient.&#xD;
&#xD;
               -  ECOG Performance Status â‰¤ 1.&#xD;
&#xD;
               -  Patients must have a site of disease amenable to biopsy, and be a candidate for&#xD;
                  tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline&#xD;
                  or at molecular pre-screening if applicable, and during therapy on this study.&#xD;
                  For patients in the phase II part of the study, exceptions may be granted after&#xD;
                  documented discussion with Novartis. After a sufficient number of paired biopsies&#xD;
                  are collected, the decision may be taken to stop the collection of biopsies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other mAbs&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic therapy.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Active HBV or HCV infection.&#xD;
&#xD;
          -  Patients with ocular melanoma.&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For&#xD;
             cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas,&#xD;
             4 weeks washout period. For patients receiving anticancer immunotherapies such as&#xD;
             CTLA-4 antagonists, 6 weeks is indicated as the washout period.&#xD;
&#xD;
          -  Prior PD-1- or PD-L1-directed therapy.&#xD;
&#xD;
          -  Patients requiring chronic treatment with systemic steroid therapy, other than&#xD;
             replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled,&#xD;
             nasal and ophthalmic steroids are not prohibited.&#xD;
&#xD;
          -  Patients receiving systemic treatment with any immunosuppressive medication (other&#xD;
             than steroids as described above).&#xD;
&#xD;
          -  Use of any vaccines against infectious diseases (e.g. influenza, varicella,&#xD;
             pneumococcus) within 4 weeks of initiation of study treatment.&#xD;
&#xD;
          -  Presence of â‰¥ CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and&#xD;
             ototoxicity, which are excluded if â‰¥ CTCAE grade 3) due to prior cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University SC-10</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI RC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center MD Anderson PSC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute Univ. of Utah HCI</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-0550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80 952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkhla</city>
        <state>Hat Yai</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I/II</keyword>
  <keyword>PDR001</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02404441/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02404441/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>58 patients were analyzed in Phase l and 261 patients were analyzed in Phase II of this study.</recruitment_details>
      <pre_assignment_details>The study planned to analyze about 58 patients in Phase I and about 120 patients in Phase II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
        </group>
        <group group_id="P2">
          <title>3mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
        </group>
        <group group_id="P3">
          <title>10mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
        </group>
        <group group_id="P4">
          <title>3mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
        </group>
        <group group_id="P5">
          <title>5mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
        </group>
        <group group_id="P6">
          <title>NSCLC 400mg/q4w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="P7">
          <title>Melanoma 400mg/q4w</title>
          <description>Phase II: Melanoma patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="P8">
          <title>TNBC 400mg/q4w</title>
          <description>Phase II: Triple negative breast cancer (TNBC) patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="P9">
          <title>NSCLC 300mg/q3w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 300 mg/q3w</description>
        </group>
        <group group_id="P10">
          <title>ATC 400 mg/q4w</title>
          <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1 Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="59"/>
                <participants group_id="P7" count="61"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="59"/>
                <participants group_id="P10" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Post-treatment Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>No Longer Being Followed for Post-treatment Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Survival Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="35"/>
                <participants group_id="P10" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="59"/>
                <participants group_id="P7" count="61"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="59"/>
                <participants group_id="P10" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="43"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="31"/>
                <participants group_id="P9" count="39"/>
                <participants group_id="P10" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
      <group_list>
        <group group_id="B1">
          <title>1mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
        </group>
        <group group_id="B2">
          <title>3mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
        </group>
        <group group_id="B3">
          <title>10mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
        </group>
        <group group_id="B4">
          <title>3mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
        </group>
        <group group_id="B5">
          <title>5mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
        </group>
        <group group_id="B6">
          <title>NSCLC 400mg/q4w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="B7">
          <title>Melanoma 400mg/q4w</title>
          <description>Phase II: Melanoma patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="B8">
          <title>TNBC 400mg/q4w</title>
          <description>Phase II: Triple negative breast cancer (TNBC) patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="B9">
          <title>NSCLC 300mg/q3w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 300 mg/q3w</description>
        </group>
        <group group_id="B10">
          <title>ATC 400 mg/q4w</title>
          <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="59"/>
            <count group_id="B7" value="61"/>
            <count group_id="B8" value="40"/>
            <count group_id="B9" value="59"/>
            <count group_id="B10" value="42"/>
            <count group_id="B11" value="319"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="25"/>
                    <measurement group_id="B11" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 65years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="39"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="50"/>
                    <measurement group_id="B10" value="33"/>
                    <measurement group_id="B11" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days)</title>
        <description>Estimated the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) for PDR001.&#xD;
AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days)</title>
          <description>Estimated the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) for PDR001.&#xD;
AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" spread="52.5"/>
                    <measurement group_id="O2" value="1150" spread="51.1"/>
                    <measurement group_id="O3" value="3110" spread="33.1"/>
                    <measurement group_id="O4" value="575" spread="21.8"/>
                    <measurement group_id="O5" value="1490" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase l: Incidence of Dose Limiting Toxicities (DLTs)</title>
        <description>DLT is defined as an adverse event (AE) or abnormal laboratory value of common terminology criteria for adverse events (CTCAE) grade â‰¥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first cycle of treatment with PDR001 during the dose escalation part of the study for which relationship to study treatment cannot be ruled out, with some exceptions.</description>
        <time_frame>8 months</time_frame>
        <population>Safety Set: The Safety Set included all subjects from the FAS who received at least one dose of spartalizumab and had at least one valid post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l: Incidence of Dose Limiting Toxicities (DLTs)</title>
          <description>DLT is defined as an adverse event (AE) or abnormal laboratory value of common terminology criteria for adverse events (CTCAE) grade â‰¥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first cycle of treatment with PDR001 during the dose escalation part of the study for which relationship to study treatment cannot be ruled out, with some exceptions.</description>
          <population>Safety Set: The Safety Set included all subjects from the FAS who received at least one dose of spartalizumab and had at least one valid post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase ll: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</title>
        <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required.&#xD;
PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O6">
            <title>All Phase II Patients</title>
            <description>All patients in Phase II regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase ll: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</title>
          <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required.&#xD;
PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="8.2" upper_limit="25.1"/>
                    <measurement group_id="O2" value="27.9" lower_limit="18.6" upper_limit="38.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O4" value="6.8" lower_limit="2.3" upper_limit="14.8"/>
                    <measurement group_id="O5" value="19.0" lower_limit="9.8" upper_limit="31.8"/>
                    <measurement group_id="O6" value="14.6" lower_limit="11.1" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Serum Pharmacokinetic (PK) Parameter AUCs (AUC0-336h (Cycle 1 Only), AUCinf, AUClast AUCtau)</title>
        <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Serum Pharmacokinetic (PK) Parameter AUCs (AUC0-336h (Cycle 1 Only), AUCinf, AUClast AUCtau)</title>
          <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle (C) 1: AUC0-336h (n=16, 13, 10, 6, 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="29.5"/>
                    <measurement group_id="O2" value="324" spread="24.4"/>
                    <measurement group_id="O3" value="1270" spread="20.3"/>
                    <measurement group_id="O4" value="350" spread="35.0"/>
                    <measurement group_id="O5" value="638" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUCinf (n = 1, 0,0,2,3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="0"/>
                    <measurement group_id="O4" value="384" spread="9.8"/>
                    <measurement group_id="O5" value="726" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUClast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="29.9"/>
                    <measurement group_id="O2" value="353" spread="31.4"/>
                    <measurement group_id="O3" value="1240" spread="21.6"/>
                    <measurement group_id="O4" value="522" spread="39.1"/>
                    <measurement group_id="O5" value="943" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUCtau (n = 16, 13, 10, 6, 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="29.5"/>
                    <measurement group_id="O2" value="324" spread="24.4"/>
                    <measurement group_id="O3" value="1270" spread="20.3"/>
                    <measurement group_id="O4" value="524" spread="39.6"/>
                    <measurement group_id="O5" value="984" spread="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUClast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" spread="44.8"/>
                    <measurement group_id="O2" value="995" spread="60.5"/>
                    <measurement group_id="O3" value="2520" spread="58.4"/>
                    <measurement group_id="O4" value="933" spread="21.3"/>
                    <measurement group_id="O5" value="2560" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUCtau (n = 8, 4, 4, 2, 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" spread="52.5"/>
                    <measurement group_id="O2" value="1150" spread="51.1"/>
                    <measurement group_id="O3" value="3110" spread="33.1"/>
                    <measurement group_id="O4" value="1040" spread="19.1"/>
                    <measurement group_id="O5" value="2770" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Serum Pharmacokinetic (PK) Parameter Cmax</title>
        <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Serum Pharmacokinetic (PK) Parameter Cmax</title>
          <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 (n = 15, 15, 10, 6, 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="26.5"/>
                    <measurement group_id="O2" value="53.8" spread="23.6"/>
                    <measurement group_id="O3" value="185" spread="18.3"/>
                    <measurement group_id="O4" value="53.8" spread="29.4"/>
                    <measurement group_id="O5" value="106" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 (n = 10, 7, 3, 3, 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="41.0"/>
                    <measurement group_id="O2" value="112" spread="27.3"/>
                    <measurement group_id="O3" value="312" spread="30.0"/>
                    <measurement group_id="O4" value="69.7" spread="9.4"/>
                    <measurement group_id="O5" value="179" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Serum Pharmacokinetic (PK) Parameter Tmax</title>
        <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Serum Pharmacokinetic (PK) Parameter Tmax</title>
          <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 (n = 15, 15, 10, 6, 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.38" upper_limit="2.12"/>
                    <measurement group_id="O2" value="1.57" lower_limit="1.25" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.13" upper_limit="1.68"/>
                    <measurement group_id="O4" value="1.55" lower_limit="1.5" upper_limit="1.83"/>
                    <measurement group_id="O5" value="1.58" lower_limit="1.08" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 (n = 10, 7, 3, 3, 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" lower_limit="1.45" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.75" upper_limit="1.58"/>
                    <measurement group_id="O3" value="1.58" lower_limit="1.52" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.5" upper_limit="1.57"/>
                    <measurement group_id="O5" value="1.3" lower_limit="0.783" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase ll: Serum Pharmacokinetic (PK) Parameter AUCs (AUC336h, AUCinf, AUClast, AUCtau)</title>
        <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase ll: Serum Pharmacokinetic (PK) Parameter AUCs (AUC336h, AUCinf, AUClast, AUCtau)</title>
          <description>AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.&#xD;
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).&#xD;
AUCinf: The AUC from time zero to infinity (mass x time x volume-1). AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1: AUC0-336h (n =58, 58, 37, 54, 37)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681" spread="39.4"/>
                    <measurement group_id="O2" value="775" spread="31.7"/>
                    <measurement group_id="O3" value="752" spread="29.3"/>
                    <measurement group_id="O4" value="535" spread="38.3"/>
                    <measurement group_id="O5" value="704" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUCinf (n = 13, 8, 7, 5, 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="29.6"/>
                    <measurement group_id="O2" value="1080" spread="45.4"/>
                    <measurement group_id="O3" value="1240" spread="25.2"/>
                    <measurement group_id="O4" value="491" spread="22.7"/>
                    <measurement group_id="O5" value="1160" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUClast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="980" spread="42.5"/>
                    <measurement group_id="O2" value="1020" spread="109.9"/>
                    <measurement group_id="O3" value="923" spread="76.1"/>
                    <measurement group_id="O4" value="602" spread="62.2"/>
                    <measurement group_id="O5" value="865" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1: AUCtau (n= 54, 55, 32, 48, 36)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1010" spread="39.8"/>
                    <measurement group_id="O2" value="1190" spread="35.0"/>
                    <measurement group_id="O3" value="1130" spread="34.9"/>
                    <measurement group_id="O4" value="689" spread="40.4"/>
                    <measurement group_id="O5" value="1070" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUC0-336h (n = 36, 49, 12, 40, 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="36.3"/>
                    <measurement group_id="O2" value="1140" spread="43.8"/>
                    <measurement group_id="O3" value="1360" spread="45.7"/>
                    <measurement group_id="O4" value="850" spread="50.6"/>
                    <measurement group_id="O5" value="1290" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUCinf (n = 1, 1, 1, 1, 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" spread="NA">N/A = Geometric coefficient of variation could not be calculated as there was only 1 patient</measurement>
                    <measurement group_id="O2" value="1070" spread="NA">N/A = Geometric coefficient of variation could not be calculated as there was only 1 patient</measurement>
                    <measurement group_id="O3" value="2340" spread="NA">N/A = Geometric coefficient of variation could not be calculated as there was only 1 patient</measurement>
                    <measurement group_id="O4" value="135" spread="NA">N/A = Geometric coefficient of variation could not be calculated as there was only 1 patient</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUClast (n = 37, 51, 16, 44, 19)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1860" spread="39.9"/>
                    <measurement group_id="O2" value="1650" spread="59.7"/>
                    <measurement group_id="O3" value="1630" spread="73.4"/>
                    <measurement group_id="O4" value="984" spread="78.0"/>
                    <measurement group_id="O5" value="1600" spread="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3: AUCtau (n= 31, 44, 7, 38, 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1940" spread="35.5"/>
                    <measurement group_id="O2" value="1790" spread="53.4"/>
                    <measurement group_id="O3" value="1920" spread="44.4"/>
                    <measurement group_id="O4" value="1100" spread="54.5"/>
                    <measurement group_id="O5" value="2120" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase ll: Serum Pharmacokinetic (PK) Parameter Cmax</title>
        <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase ll: Serum Pharmacokinetic (PK) Parameter Cmax</title>
          <description>The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 (n = 52, 58, 32, 55, 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="37.0"/>
                    <measurement group_id="O2" value="111" spread="26.6"/>
                    <measurement group_id="O3" value="114" spread="23.6"/>
                    <measurement group_id="O4" value="79.9" spread="31.8"/>
                    <measurement group_id="O5" value="100" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 (n = 33, 45, 11, 39, 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" spread="32.0"/>
                    <measurement group_id="O2" value="141" spread="33.4"/>
                    <measurement group_id="O3" value="163" spread="34.7"/>
                    <measurement group_id="O4" value="103" spread="36.6"/>
                    <measurement group_id="O5" value="146" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase ll: Serum Pharmacokinetic (PK) Parameter Tmax</title>
        <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
        <time_frame>Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (Cycle 1 &amp; 3)</time_frame>
        <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase ll: Serum Pharmacokinetic (PK) Parameter Tmax</title>
          <description>The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
          <population>Pharmacokinetic analysis set (PAS): The PAS consisted of all subjects who had at least one blood sample providing evaluable PK data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 (n= 52, 58, 32, 55, 35)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="0.55" upper_limit="2.52"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.07" upper_limit="2.9"/>
                    <measurement group_id="O3" value="1.58" lower_limit="1.18" upper_limit="2.15"/>
                    <measurement group_id="O4" value="1.65" lower_limit="1.00" upper_limit="3.08"/>
                    <measurement group_id="O5" value="1.55" lower_limit="0.5" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 (n = 33, 45, 11, 39, 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.983" upper_limit="2.08"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.07" upper_limit="2.22"/>
                    <measurement group_id="O3" value="1.53" lower_limit="1.42" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.33" upper_limit="2.92"/>
                    <measurement group_id="O5" value="1.57" lower_limit="0" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Presence and/or Concentration of Anti-PDR001</title>
        <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.</description>
        <time_frame>42 months</time_frame>
        <population>Immunogenicity incidence Set: The Immunogenicity incidence set includes all subjects in FAS with a determinant baseline immunoglobulin (IG) sample and at least one determinant post-baseline IG sample.&#xD;
Treatment-induced ADA-positive was performed on ADA-positive patients only. Treatment-boosted ADA-positive was performed on ADA-positive patients only.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O5">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O7">
            <title>All Phase I q4w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
          </group>
          <group group_id="O8">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Presence and/or Concentration of Anti-PDR001</title>
          <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.</description>
          <population>Immunogenicity incidence Set: The Immunogenicity incidence set includes all subjects in FAS with a determinant baseline immunoglobulin (IG) sample and at least one determinant post-baseline IG sample.&#xD;
Treatment-induced ADA-positive was performed on ADA-positive patients only. Treatment-boosted ADA-positive was performed on ADA-positive patients only.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with ADA-negative sample at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with ADA-positive sample at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-positive (i.e., ADA incidence)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-induced ADA-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Presence and/or Concentration of Anti-PDR001</title>
        <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.&#xD;
For Treatment -induced ADA-positive, Percentage was based on subjects ADA-negative at baseline.&#xD;
For Treatment-boosted ADA-positive, Percentage was based on subjects ADA-positive at baseline.</description>
        <time_frame>42 months</time_frame>
        <population>Immunogenicity incidence Set: The Immunogenicity incidence set includes all subjects in FAS with a determinant baseline immunoglobulin (IG) sample and at least one determinant post-baseline IG sample.</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O6">
            <title>All Phase II Patients</title>
            <description>All patients in Phase II regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Presence and/or Concentration of Anti-PDR001</title>
          <description>Assessed PDR001 anti-drug anti-body (ADA) incidence in Phase I patients - the emergence of anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of PDR001. Each cycle = 28 days; End of treatment was expected to be on average 1 year after the start of study treatment.&#xD;
For Treatment -induced ADA-positive, Percentage was based on subjects ADA-negative at baseline.&#xD;
For Treatment-boosted ADA-positive, Percentage was based on subjects ADA-positive at baseline.</description>
          <population>Immunogenicity incidence Set: The Immunogenicity incidence set includes all subjects in FAS with a determinant baseline immunoglobulin (IG) sample and at least one determinant post-baseline IG sample.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with ADA-negative sample at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with ADA-positive sample at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-positive (i.e., ADA incidence)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-induced ADA-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l: Overall Response Rate (ORR) as Per Investigator Based on RECIST v1.1</title>
        <description>ORR is the percentage of participants with a best overall response of complete response CR or partial response PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O5">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O7">
            <title>All Phase I q4w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
          </group>
          <group group_id="O8">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l: Overall Response Rate (ORR) as Per Investigator Based on RECIST v1.1</title>
          <description>ORR is the percentage of participants with a best overall response of complete response CR or partial response PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="17.1"/>
                    <measurement group_id="O2" value="6.7" lower_limit="0.3" upper_limit="27.9"/>
                    <measurement group_id="O3" value="9.1" lower_limit="0.5" upper_limit="36.4"/>
                    <measurement group_id="O4" value="4.8" lower_limit="0.9" upper_limit="14.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="39.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="25.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="17.1"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.6" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</title>
        <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O5">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O7">
            <title>All Phase I q4w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
          </group>
          <group group_id="O8">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</title>
          <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="33.3" upper_limit="77.3"/>
                    <measurement group_id="O2" value="46.7" lower_limit="24.4" upper_limit="70.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="7.9" upper_limit="56.4"/>
                    <measurement group_id="O4" value="45.2" lower_limit="32.0" upper_limit="59.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="15.3" upper_limit="84.7"/>
                    <measurement group_id="O6" value="20.0" lower_limit="3.7" upper_limit="50.7"/>
                    <measurement group_id="O7" value="31.3" lower_limit="13.2" upper_limit="54.8"/>
                    <measurement group_id="O8" value="41.4" lower_limit="30.4" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l: Progression Free Survival (PFS) as Per RECIST v1.1</title>
        <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l: Progression Free Survival (PFS) as Per RECIST v1.1</title>
          <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.5" upper_limit="8.1"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.7" upper_limit="5.8"/>
                    <measurement group_id="O4" value="2.7" lower_limit="1.1" upper_limit="3.5"/>
                    <measurement group_id="O5" value="1.8" lower_limit="1.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Duration of Response (DOR) as Per RECIST v1.1</title>
        <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented. CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required; PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required; PD =progression &lt;= 12 weeks after randomization/start of treatment (and not qualifying for CR, PR or SD). SD = at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR). RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment</description>
        <time_frame>27 months</time_frame>
        <population>Full analysis set - Dose escalation</population>
        <group_list>
          <group group_id="O1">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Duration of Response (DOR) as Per RECIST v1.1</title>
          <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented. CR = at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required; PR = at least 2 determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required; PD =progression &lt;= 12 weeks after randomization/start of treatment (and not qualifying for CR, PR or SD). SD = at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR). RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment</description>
          <population>Full analysis set - Dose escalation</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.00" lower_limit="261.0" upper_limit="261.0"/>
                    <measurement group_id="O2" value="55.00" lower_limit="55.0" upper_limit="55.0"/>
                    <measurement group_id="O3" value="158.00" lower_limit="55.0" upper_limit="261.0"/>
                    <measurement group_id="O4" value="158.00" lower_limit="55.0" upper_limit="261.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l Only: Overall Response Rate (ORR) as Per Investigator Based on Immune Related Response Criteria (irRC)</title>
        <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O5">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O7">
            <title>All Phase I q4w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
          </group>
          <group group_id="O8">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l Only: Overall Response Rate (ORR) as Per Investigator Based on Immune Related Response Criteria (irRC)</title>
          <description>ORR is the percentage of participants with a best overall response of complete response (CR) or partial response (PR) as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="17.1"/>
                    <measurement group_id="O2" value="6.7" lower_limit="0.3" upper_limit="27.9"/>
                    <measurement group_id="O3" value="9.1" lower_limit="0.5" upper_limit="36.4"/>
                    <measurement group_id="O4" value="4.8" lower_limit="0.9" upper_limit="14.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="39.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="25.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="17.1"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.6" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l Only: Disease Control Rate (DCR) as Per Investigator Based on irRC</title>
        <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O5">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O7">
            <title>All Phase I q4w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
          </group>
          <group group_id="O8">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l Only: Disease Control Rate (DCR) as Per Investigator Based on irRC</title>
          <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="39.1" upper_limit="82.2"/>
                    <measurement group_id="O2" value="53.3" lower_limit="30.0" upper_limit="75.6"/>
                    <measurement group_id="O3" value="27.3" lower_limit="7.9" upper_limit="56.4"/>
                    <measurement group_id="O4" value="50.0" lower_limit="36.5" upper_limit="63.5"/>
                    <measurement group_id="O5" value="50.0" lower_limit="15.3" upper_limit="84.7"/>
                    <measurement group_id="O6" value="30.0" lower_limit="8.7" upper_limit="60.7"/>
                    <measurement group_id="O7" value="37.5" lower_limit="17.8" upper_limit="60.9"/>
                    <measurement group_id="O8" value="46.6" lower_limit="35.3" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase l Only: Progression Free Survival (PFS) as Per irRC</title>
        <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>27 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase l Only: Progression Free Survival (PFS) as Per irRC</title>
          <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.8" upper_limit="NA">N/A: Model could not compute the upper limit of CI due to small sample size</measurement>
                    <measurement group_id="O2" value="2.7" lower_limit="1.5" upper_limit="8.1"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.7" upper_limit="5.8"/>
                    <measurement group_id="O4" value="2.7" lower_limit="1.1" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.8" lower_limit="1.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Duration of Response (DOR) as Per irRC</title>
        <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
        <time_frame>61 Days</time_frame>
        <population>Full analysis set - Dose escalation</population>
        <group_list>
          <group group_id="O1">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>All Phase I q2w</title>
            <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
          </group>
          <group group_id="O4">
            <title>All Phase I Patients</title>
            <description>All patients in Phase I regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Duration of Response (DOR) as Per irRC</title>
          <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
          <population>Full analysis set - Dose escalation</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.00" lower_limit="261.0" upper_limit="261.0"/>
                    <measurement group_id="O2" value="55.00" lower_limit="55.0" upper_limit="55.0"/>
                    <measurement group_id="O3" value="158.00" lower_limit="55.0" upper_limit="261.0"/>
                    <measurement group_id="O4" value="158.00" lower_limit="55.0" upper_limit="261.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</title>
        <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O6">
            <title>All Phase II Patients</title>
            <description>All patients in Phase II regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Disease Control Rate (DCR) as Per Investigator Based on RECIST v1.1</title>
          <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="37.8" upper_limit="60.5"/>
                    <measurement group_id="O2" value="62.3" lower_limit="51.0" upper_limit="72.7"/>
                    <measurement group_id="O3" value="20.0" lower_limit="10.4" upper_limit="33.2"/>
                    <measurement group_id="O4" value="35.6" lower_limit="25.2" upper_limit="47.1"/>
                    <measurement group_id="O5" value="31.0" lower_limit="19.4" upper_limit="44.6"/>
                    <measurement group_id="O6" value="41.8" lower_limit="36.6" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Progression Free Survival as Per Investigator Based on RECIST v1.1</title>
        <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Progression Free Survival as Per Investigator Based on RECIST v1.1</title>
          <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
RECIST criteria, published in February 2000 by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, is a Response evaluation criteria in solid tumors is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.9" upper_limit="5.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.5" upper_limit="5.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.8" upper_limit="2.1"/>
                    <measurement group_id="O5" value="1.7" lower_limit="1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Duration of Response (DOR) as Per Investigator Based on RECIST v1.1</title>
        <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
PD = progression &lt;= start of treatment (and not qualifying for CR, PR or SD). SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O4">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Duration of Response (DOR) as Per Investigator Based on RECIST v1.1</title>
          <description>DOR is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
PD = progression &lt;= start of treatment (and not qualifying for CR, PR or SD). SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
RECIST criteria is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="32.0" lower_limit="11.1" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to small sample size'</measurement>
                    <measurement group_id="O3" value="10.9" lower_limit="3.7" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to small sample size</measurement>
                    <measurement group_id="O4" value="22.8" lower_limit="5.7" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Overall Response Rate (ORR) as Per Investigator Based on irRC</title>
        <description>ORR is the percentage of participants with a best overall response CR or PR as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O6">
            <title>All Phase II Patients</title>
            <description>All patients in Phase II regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Overall Response Rate (ORR) as Per Investigator Based on irRC</title>
          <description>ORR is the percentage of participants with a best overall response CR or PR as per irRC.&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required.&#xD;
PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="10.8" upper_limit="29.0"/>
                    <measurement group_id="O2" value="31.1" lower_limit="21.5" upper_limit="42.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O4" value="8.5" lower_limit="3.4" upper_limit="17.0"/>
                    <measurement group_id="O5" value="23.8" lower_limit="13.5" upper_limit="37.0"/>
                    <measurement group_id="O6" value="17.2" lower_limit="13.5" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Disease Control Rate (DCR) as Per Investigator Based on irRC</title>
        <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O6">
            <title>All Phase II Patients</title>
            <description>All patients in Phase II regardless of how they took PDR001</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Disease Control Rate (DCR) as Per Investigator Based on irRC</title>
          <description>DCR is the percentage of patients with a best overall response of CR or PR or stable disease (SD).&#xD;
CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required.&#xD;
SD = at least one SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (and not qualifying for CR or PR).&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" lower_limit="44.4" upper_limit="67.0"/>
                    <measurement group_id="O2" value="67.2" lower_limit="56.0" upper_limit="77.1"/>
                    <measurement group_id="O3" value="22.5" lower_limit="12.3" upper_limit="36.0"/>
                    <measurement group_id="O4" value="39.0" lower_limit="28.3" upper_limit="50.5"/>
                    <measurement group_id="O5" value="35.7" lower_limit="23.5" upper_limit="49.5"/>
                    <measurement group_id="O6" value="46.4" lower_limit="41.1" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Progression Free Survival (PFS) Per irRC</title>
        <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O4">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O5">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Progression Free Survival (PFS) Per irRC</title>
          <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is per Kaplan-Meier estimates.&#xD;
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug.</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.6" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.4" lower_limit="3.7" upper_limit="6.5"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.7" upper_limit="1.8"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.8" upper_limit="2.2"/>
                    <measurement group_id="O5" value="1.7" lower_limit="1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Duration of Response (DOR) Per irRC</title>
        <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
        <time_frame>61 months</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O3">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O4">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Duration of Response (DOR) Per irRC</title>
          <description>DOR: measured from time measurement criteria are met for CR or PR (whichever status is recorded first) until first date that recurrence or PD is objectively documented CR: at least 2 determinations of CR at least 4 weeks apart before progression where confirmation required or 1 determination of CR prior to progression where confirmation not required PR: at least 1 determination of PR or better at least 4 weeks apart before progression (&amp; not qualifying for a CR) where confirmation required or 1 determination of PR prior to progression where confirmation not required PD: progression &lt;= start of treatment (&amp; not qualifying for CR, PR or SD) SD: at least 1 SD assessment (or better) &gt; 6 weeks after randomization/start of treatment (&amp; not qualifying for CR or PR) irRC is a set of published rules that define when tumors in cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;), or worsen (&quot;progress&quot;) during treatment, where the compound being evaluated is an immuno-oncology drug</description>
          <population>Full Analysis Set (FAS): The FAS included all subjects who received at least one dose of spartalizumab. Subjects were analyzed according to the planned treatment (dose level and regimen).</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.3" upper_limit="16.6"/>
                    <measurement group_id="O2" value="32.0" lower_limit="15.6" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to small sample size</measurement>
                    <measurement group_id="O3" value="10.9" lower_limit="3.7" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to small sample size</measurement>
                    <measurement group_id="O4" value="22.1" lower_limit="3.8" upper_limit="NA">N/A = Model could not compute the upper limit of CI due to sparse data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>On treatment deaths were collected from the start of study treatment up to 30 days after last study treatment exposure, for a maximum duration of 114.3 weeks for Phase I part (treatment duration ranged from 2 to 110.3 weeks) and a maximum duration of 194.9 weeks for Phase II part (treatment duration ranged from 0.6 tp 190.9 weeks).&#xD;
Total deaths were collected from the start of treatment up to end of follow-up phase (approx. 70 months).</description>
        <time_frame>On treatment deaths: approx. 114.3 weeks (Phase I) &amp; 194.9 weeks (phase II), all deaths: approx. 70 months</time_frame>
        <population>Clinical database population: All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
          </group>
          <group group_id="O2">
            <title>3mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
          </group>
          <group group_id="O3">
            <title>10mg/kg q2w</title>
            <description>Phase I Dose escalation cohort patients who took PDR001 10 mg/kg q2w</description>
          </group>
          <group group_id="O4">
            <title>3mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
          </group>
          <group group_id="O5">
            <title>5mg/kg q4w</title>
            <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
          </group>
          <group group_id="O6">
            <title>NSCLC 400 mg/q4w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O7">
            <title>Melanoma 400 mg/q4w</title>
            <description>Patients in Phase II with Melanoma who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O8">
            <title>TNBC 400 mg/q4w</title>
            <description>Patients in Phase II with TNBC who took PDR001 400 mg/q4w</description>
          </group>
          <group group_id="O9">
            <title>NSCLC 300 mg/q3w</title>
            <description>Patients in Phase II with non-small cell cancer who took PDR001 300 mg/q3w</description>
          </group>
          <group group_id="O10">
            <title>ATC 400 mg/q4w</title>
            <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>On treatment deaths were collected from the start of study treatment up to 30 days after last study treatment exposure, for a maximum duration of 114.3 weeks for Phase I part (treatment duration ranged from 2 to 110.3 weeks) and a maximum duration of 194.9 weeks for Phase II part (treatment duration ranged from 0.6 tp 190.9 weeks).&#xD;
Total deaths were collected from the start of treatment up to end of follow-up phase (approx. 70 months).</description>
          <population>Clinical database population: All treated patients</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="59"/>
                <count group_id="O10" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On-treatment deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On treatment deaths were collected from the start of study treatment up to 30 days after last study treatment exposure, for a maximum duration of 114.3 weeks for the Part I phase (treatment duration ranged from 2 to 110.3 weeks) and for a maximum duration of 194.9 weeks for the Phase II part (treatment duration ranged from 0.6 to 190.9 weeks).</time_frame>
      <desc>AE: Any sign or symptom that occurs during treatment plus 30 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>1mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w</description>
        </group>
        <group group_id="E2">
          <title>3mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w</description>
        </group>
        <group group_id="E3">
          <title>10mg/kg q2w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 10 mg/kg q2w</description>
        </group>
        <group group_id="E4">
          <title>All Phase I q2w</title>
          <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q2w</description>
        </group>
        <group group_id="E5">
          <title>3mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q4w</description>
        </group>
        <group group_id="E6">
          <title>5mg/kg q4w</title>
          <description>Phase I Dose escalation cohort patients who took PRD001 5 mg/kg q4w</description>
        </group>
        <group group_id="E7">
          <title>All Phase I q4w</title>
          <description>Phase I dose Cohorts - All patients in Phase I who took PDR001 q4w</description>
        </group>
        <group group_id="E8">
          <title>All Phase I Patients</title>
          <description>All patients in Phase I regardless of how they took PDR001</description>
        </group>
        <group group_id="E9">
          <title>NSCLC 400mg/q4w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="E10">
          <title>Melanoma 400mg/q4w</title>
          <description>Phase II: Melanoma patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="E11">
          <title>TNBC 400mg/q4w</title>
          <description>Phase II: Triple negative breast cancer (TNBC) patients who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="E12">
          <title>NSCLC 300mg/q3w</title>
          <description>Phase II: non-small cell cancer patients who took PDR001 300 mg/q3w</description>
        </group>
        <group group_id="E13">
          <title>ATC 400 mg/q4w</title>
          <description>Patients in Phase II with anaplastic thyroid cancer (ATC) who took PDR001 400 mg/q4w</description>
        </group>
        <group group_id="E14">
          <title>All Phase II Patients</title>
          <description>All patients in Phase II regardless of how they took PDR001</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="35" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="37" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="126" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Complication of device insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Second primary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tumour inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="58" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="54" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="55" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="56" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="39" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="241" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="54" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="18" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="38" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="37" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="45" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pancreatic duct dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="32" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="44" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="54" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="24" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="41" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Laryngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="22" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="25" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="24" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="60" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="27" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="27" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="19" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="23" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="22" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="19" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="57" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="55" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="27" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="20" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the study had 2 'arms', the phase I part of the study had 5 dosing cohorts and the phase ll part had 5 treatment groups for a total of 10 reporting groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

